Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

locally in the vagina. No SERMs that are currently approved and marketed in the United States have been shown to have beneficial effects on vaginal tissue and none are approved for use in treating vaginal symptoms.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in clinical development and an advanced preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta-HSD enzymes. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases and other Company information, please visit www.quatrx.com.


'/>"/>
SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Dow Jones Sustainability Indexes for Six Consecutive Years... -- ABBOTT PARK, Ill., Sept. 9 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... Pharmaceuticals, LLC announced today the approval of a new, ... 0.0375%, for the treatment of acne vulgaris. An excellent ... between strength – effective yet gentle. Tretin-X 0.0375% ... those patients already on tretinoin therapy for acne, Tretin-X ...
Cached Medicine Technology:Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 2Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 3Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 4Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 5Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 6Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 7Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 8New, Exclusive Strength: Tretin-X® 0.0375%(tretinoin) Cream 2
(Date:7/11/2014)... Butler Mobility has recently updated the paint ... . Previously the two standard colors were beige and ... tone colors as standard colors at no additional charge! ... but will enhance the beauty of the stairway. Homeowners ... scheme or individual décor. , The new selection of standard ...
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... 2014 Utilizing the Keller Funnel, ... Koenig, has topped a record number of complication-free breast ... over 400 successful procedures without the occurrence of a ... known across the country for his expertise with the ... long been the foundation for numerous studies and research. ...
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ... These also help turf and ornamentals in absorption of ... ornamentals, and flowers appear healthy and strong as a ... from the last few years. The most dominating region ... with around 40% share in 2013, and is estimated ...
Breaking Medicine News(10 mins):Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... Through exercise, it seems to boost activity in a key ... -- U.S. researchers say they,ve developed a hand-exercising robotic device ... more than six months after a stroke. , Brain ... stroke-afflicted hands, boosted activity in the part of the brain ...
... Sheets: GOHE) announced today that the company has gained over 60 ... Recovery Shakes and Bars, including many of the top names of ... , Stuart Evey, Chairman of Go Healthy and formerly ... products are received by athletes and coaches. Implementation of sales ...
... Mass., Dec. 4 Decision Resources, one of ... pharmaceutical and,healthcare issues, finds that Eisai/Helsinn Healthcare,s Aloxi,s ... rated the most influential,by oncologists in the chemotherapy-induced ... messages with the brand,highlighting the strength of the ...
... Integration with McKesson PACS and Kodak Carestream to ... , , CHICAGO, ... disparate healthcare IT systems, and Medical Imaging Northwest ... Enterprise-wide worklist solution, integrating digital imaging and data ...
... New York Medicaid Managed Care Model Compliance Guidance ... 4 The Health Care Compliance Association (HCCA) announced ... Compliance conference, February 22-24, 2009, in Scottsdale, Arizona. The ... for the industry, is intended to provide essential information ...
... Celebrity duo bring sports flavor to the conversation about a ... CARY, N.C., Dec. 4 College basketball analyst ... Pardon the Interruption Michael Wilbon have teamed up with ESPN, ... Cancer(TM) in an effort to create a national discussion about ...
Cached Medicine News:Health News:Robotic Device Could Help Stroke Patients 2Health News:Robotic Device Could Help Stroke Patients 3Health News:Go Healthy Updates Progress With University Sports Programs 2Health News:Oncologists Rank Aloxi's Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market 2Health News:Medical Imaging Northwest Selects Compressus for Enterprise Interoperability 2Health News:Medical Imaging Northwest Selects Compressus for Enterprise Interoperability 3Health News:Medical Imaging Northwest Selects Compressus for Enterprise Interoperability 4Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 2Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 3Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 2Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 3Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: